Cardiol Therapeutics Inc. (CRDR) is a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart diseases. The company is a Canadian-based biotechnology company that pioneers the research and commercial production of premium, pharmaceutical-grade CBD and pursues the clinical development of pure CBD therapies for severe cardiovascular diseases.
Primarily, Cardiol Therapeutics focuses on the heart failure market, which is the leading cause of death and hospitalization in North America, with associated annual healthcare costs exceeding $30 billion. Cardiol's primary drug candidate, CardiolRx™, is designed to be the safest and most consistent CBD formulation available.
Cardiol's pharmaceutical strategy is to commercially produce CardiolRx™, a pharmaceutically-produced cannabidiol formulation that does not contain THC (the psychoactive component of cannabis) for distribution in the billion-dollar market for medicinal cannabinoids in Canada and for pursuing breakthrough, orphan drug applications for acute myocarditis, which is an inflammation of the heart muscle, and other causes of heart failure worldwide.
In addition to pharmaceutical CBD, Cardiol also develops nanotherapeutics to treat heart failure. Their patented nanotechnology is used to deliver anti-inflammatory drugs directly to the inflamed heart tissue associated with heart diseases, enhancing the treatment's efficacy while reducing side effects.
Cardiol is driven by a team of scientific and medical professionals, experienced in pharmaceutical product development and commercialization and passionate about pioneering new paths in cardiovascular medicine. The company believes in research, innovation, and developing new therapies that could potentially change the prognosis for thousands of heart disease patients around the world.
In addition to their commitment to groundbreaking medical advancements, Cardiol Therapeutics places significant importance on social responsibility. They operate in line with Good Manufacturing Practices, ensuring the highest quality products, and they are committed to the ethical and sustainable sourcing of their ingredients.
All in all, Cardiol Therapeutics Inc. (CRDL) is committed to the research and development of innovative therapies that have the potential to change lives for the better and strives to continue to deliver high-quality, pharmaceutically-produced CBD products for medical use.